AQSZF: AI 评分 59/100 — AI 分析 (4月 2026)

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing drugs in neurology, ophthalmology, and transplantation. The company markets products like Vistitan for glaucoma and Evolve dry eye products, while also developing extended-release treatments for epilepsy and cannabinoid-based therapeutics.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

Aequus Pharmaceuticals Inc., based in Canada, specializes in developing and commercializing drugs for neurology, ophthalmology, and transplantation. With products like Vistitan and Evolve, alongside a pipeline of extended-release and cannabinoid-based therapies, Aequus operates in the competitive specialty pharmaceutical market, collaborating with partners like Sandoz and Supernus.

AQSZF是做什么的？

Aequus Pharmaceuticals Inc., established in 2013 and headquartered in Vancouver, Canada, is a specialty pharmaceutical company dedicated to the development and commercialization of differentiated products. The company focuses on addressing unmet needs in neurology, ophthalmology, and transplantation. Aequus markets Vistitan, an ophthalmology product used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It also offers Tacrolimus IR, an immunosuppressant used to prevent acute rejection following organ transplantation, and the Evolve line of dry eye products. In addition to its marketed products, Aequus has a pipeline of development-stage products, including Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. The company is also developing AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy, and AQS1304, a cannabinoid-based therapeutic for neurological disorders. Aequus collaborates with Sandoz Canada, Inc. for the promotion of Vistitan, Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic drugs, and Medicom Healthcare Ltd. to focus on preservative-free therapies in ophthalmology. With a small team of 12 employees, Aequus operates primarily in the Canadian market, seeking to expand its product offerings and partnerships.

AQSZF的投资论点是什么？

Aequus Pharmaceuticals operates in niche healthcare markets, offering potential for growth through its existing product portfolio and development pipeline. The company's focus on ophthalmology, neurology, and transplantation provides diversification. Key value drivers include successful commercialization of pipeline products like Topiramate XR and AQS1304, expansion of existing product sales, and strategic partnerships. However, the company's negative profit margin of -71.5% and small market capitalization present risks. Investors should monitor the progress of clinical trials, regulatory approvals, and the company's ability to achieve profitability. The company's beta of -0.28 suggests low volatility relative to the market.

AQSZF在哪个行业运营？

Aequus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and stringent regulatory requirements. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. Companies like Aequus focus on niche therapeutic areas to differentiate themselves. The industry is also influenced by pricing pressures, generic drug penetration, and the need for continuous innovation. Aequus's collaborations and focus on specific therapeutic areas position it to capitalize on market trends.

Drug Manufacturers - Specialty & Generic

Healthcare

AQSZF有哪些增长机遇？

Expansion of Ophthalmology Product Line: Aequus can expand its Evolve dry eye product line and Vistitan sales by targeting a larger market share within the growing ophthalmology sector. The global dry eye syndrome market is projected to reach $6.5 billion by 2028, offering a substantial opportunity for Aequus to increase revenue through innovative formulations and expanded distribution channels. This expansion can be realized within the next 2-3 years through strategic marketing and partnerships.
Advancement of Epilepsy Pipeline: The development and commercialization of Topiramate XR and Oxcarbazepine XR extended-release oral tablets for epilepsy represent a significant growth opportunity. The global epilepsy market is expected to reach $11 billion by 2027. Successful clinical trials and regulatory approvals could position Aequus to capture a portion of this market, potentially generating substantial revenue streams starting in 2028.
Commercialization of Cannabinoid Therapeutics: Aequus's AQS1304, a cannabinoid-based therapeutic for neurological disorders, presents a novel growth avenue. The increasing acceptance of cannabinoid-based therapies for various neurological conditions offers a promising market. The global cannabinoid market is projected to reach $47 billion by 2027. Aequus could potentially launch this product within the next 3-5 years, pending regulatory approvals and clinical trial outcomes.
Strategic Partnerships and Collaborations: Aequus can leverage strategic partnerships to expand its market reach and product portfolio. Collaborations with companies like Sandoz and Supernus have already proven beneficial. Seeking additional partnerships for distribution, co-development, or licensing agreements can accelerate growth and reduce risk. These partnerships can be forged within the next 1-2 years, enhancing Aequus's market presence and innovation capabilities.
Geographic Expansion Beyond Canada: While currently focused on the Canadian market, Aequus can explore opportunities for geographic expansion into other regions, such as the United States or Europe. This expansion could involve partnering with local distributors or establishing a direct presence. The global pharmaceutical market offers vast opportunities, and strategic geographic expansion can significantly increase Aequus's revenue base over the next 3-5 years.

Aequus Pharmaceuticals focuses on specialty pharmaceuticals within neurology, ophthalmology, and transplantation.
The company markets Vistitan for glaucoma, addressing a significant market need.
Aequus has a development pipeline including extended-release anti-epileptic drugs and cannabinoid-based therapeutics.
The company maintains strategic collaborations with Sandoz, Supernus, and Medicom Healthcare.
Aequus Pharmaceuticals has a gross margin of 53.3% indicating potential profitability from its products.

AQSZF提供哪些产品和服务？

Develops and commercializes specialty pharmaceutical products.
Focuses on therapeutic areas including neurology, ophthalmology, and transplantation.
Markets Vistitan to reduce intraocular pressure in glaucoma patients.
Offers Tacrolimus IR for the prevention of organ rejection.
Provides Evolve dry eye products for dry eye disease and blepharitis.
Develops extended-release oral tablets for the treatment of epilepsy.
Develops cannabinoid-based therapeutics for neurological disorders.

AQSZF如何赚钱？

Develops and acquires rights to specialty pharmaceutical products.
Commercializes products through direct sales and marketing efforts.
Partners with other pharmaceutical companies for distribution and promotion.
Generates revenue through product sales and licensing agreements.

Patients with glaucoma and ocular hypertension.
Patients undergoing organ transplantation.
Patients with dry eye disease and blepharitis.
Patients with epilepsy and other neurological disorders.

Specialty Focus: Niche therapeutic areas provide less competition.
Product Portfolio: Diversified product offerings across multiple therapeutic areas.
Strategic Partnerships: Collaborations with established pharmaceutical companies.
Development Pipeline: Pipeline of new products in development.

什么因素可能推动AQSZF股价上涨？

Upcoming: Clinical trial results for Topiramate XR and Oxcarbazepine XR extended-release tablets for epilepsy.
Upcoming: Regulatory approval decisions for AQS1303 for the treatment of nausea and vomiting of pregnancy.
Upcoming: Potential new partnerships for distribution or co-development of products.
Ongoing: Expansion of the Evolve dry eye product line into new markets.
Ongoing: Continued growth in sales of Vistitan for glaucoma.

AQSZF的主要风险是什么？

Potential: Clinical trial failures for development-stage products.
Potential: Regulatory delays or rejections for new product approvals.
Potential: Increased competition from larger pharmaceutical companies.
Ongoing: Pricing pressures and generic drug penetration.
Ongoing: Dependence on partnerships for distribution and commercialization.

AQSZF的核心优势是什么？

Focus on niche therapeutic areas.
Existing product portfolio with established revenue streams.
Strategic partnerships with larger pharmaceutical companies.
Development pipeline of new products.

AQSZF的劣势是什么？

Small market capitalization.
Negative profit margin.
Limited geographic reach.
Reliance on partnerships for distribution.

AQSZF有哪些机遇？

Expansion into new therapeutic areas.
Geographic expansion into new markets.
Acquisition of new products or technologies.
Increased demand for specialty pharmaceuticals.

AQSZF面临哪些威胁？

Competition from larger pharmaceutical companies.
Regulatory challenges and delays.
Pricing pressures and generic drug penetration.
Clinical trial failures.

AQSZF的竞争对手是谁？

Acutus Medical, Inc. — Focuses on cardiac arrhythmia solutions. — (ACUS)
Bioasis Technologies Inc. — Develops xB3 platform for drug delivery across the blood-brain barrier. — (BIOAF)
Enviro Technologies U.S., Inc. — Focuses on developing green solutions. — (DVLP)
HempMeds Mexico, Inc. — Specializes in cannabis-based health products. — (HPMM)
Invixium Access Inc. — Provides biometric access control solutions. — (IVIXF)

Key Metrics

MoonshotScore: 59/100

Company Profile

CEO: Douglas Glen Janzen
Headquarters: Vancouver, CA
Employees: 12
Founded: 2015

AI Insight

AI analysis pending for AQSZF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aequus Pharmaceuticals Inc. do?

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company that develops and commercializes drugs in the therapeutic areas of neurology, ophthalmology, and transplantation. The company markets products like Vistitan for glaucoma and Evolve dry eye products. Aequus also has a development pipeline that includes extended-release anti-epileptic drugs and cannabinoid-based therapeutics for neurological disorders. The company focuses on addressing unmet medical needs through innovative products and strategic partnerships.

What do analysts say about AQSZF stock?

As of March 16, 2026, there is no readily available analyst consensus on AQSZF stock due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-1.01) and profit margin (-71.5%) reflect the company's current financial challenges. Growth considerations include the successful development and commercialization of pipeline products and expansion of existing product sales. Investors should conduct independent research and consider the risks associated with investing in OTC-listed companies.

What are the main risks for AQSZF?

The main risks for Aequus Pharmaceuticals Inc. include clinical trial failures for its development-stage products, regulatory delays or rejections for new product approvals, and increased competition from larger pharmaceutical companies. The company's small market capitalization and negative profit margin also pose financial risks. Dependence on partnerships for distribution and commercialization adds another layer of risk. Investors should carefully consider these factors before investing in AQSZF.